Stock Groups

Merck applies for U.S. emergency authorization of COVID-19 pill By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

(Reuters) – Merck & Co Inc said on Monday it has applied for emergency use authorization in the United States for its oral drug to treat mild-to-moderate patients of COVID-19.

Ridgeback Biotherapeutics developed the treatment, molnupiravir. This would be the world’s first approved oral antiviral drug.

Last week’s data showed that patients most at-risk of severe COVID-19 could have their chances reduced by half or even a complete stoppage of treatment with molnupiravir.

Included in existing drugs are Gilead Sciences Inc (NASDAQ: )’s Infused Antiviral Remdesivir and Generic Steroid Dexamethasone are typically only available to hospitalized patients.

Due to their difficulty of administration, monoclonal antibodies drugs have seen limited use.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]